Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions

European Heart Journal

Volumn 27, Issue 5, 2006, Pages 547-552

  Atar, Ilyas ^a   Korkmaz, Mehmet Emin ^a   Atar, Inci Asli ^a   Gulmez, Oyku ^a   Ozin, Bulent ^a   Bozbas, Huseyin ^a   Erol, Tansel ^a   Aydinalp, Alp ^a   Yildirir, Aylin ^a   Yucel, Muammer ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Beta blocker; Cardiac troponin I; Percutaneous coronary interventions

Indexed keywords

BELOC ZOC; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL SUCCINATE; NITRATE; TICLOPIDINE; TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PRESSURE; CORONARY ARTERIOSCLEROSIS; CORONARY STENOSIS; CREATINE KINASE, MB FORM; DELAYED-ACTION PREPARATIONS; FEMALE; HEART RATE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SURGICAL PROCEDURES, ELECTIVE; TROPONIN I;

EID: 33645236691     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi709     Document Type: Article

References (32)

1. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM; SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738-1744.
2. Garbarz E, Iung B, Lefevre G, Makita Y, Farah B, Michaud P, Graine H, Vahanian A. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol 1999; 84:515-518.
3. Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, Kent KM, Clark CE, Stone GW, Leon MB. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000;85:1077-1082.
4. Herrmann J, Von Birgelen C, Haude M, Volbracht L, Malyar N, Eggebrecht H, Konorza TF, Baumgart D, Erbel R. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 2002;87:549-553.
5. Bertinchant JP, Polge A, Ledermann B, Genet L, Fabbro-Peray P, Raczka F, Brunet J, Poirey S, Wittenberg O, Pernel I, Nigond J. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol 1999;84:51-57.
6. Johansen O, Brekke M, Stromme JH, Valen V, Seljeflot I, Skjaeggestad O, Arnesen H. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J 1998;19:112-117.
7. Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, Sharma SK. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004;93:18-23.
8. Mandadi VR, DeVoe MC, Ambrose JA, Prakash AM, Varshneya N, Gould RB, Nguyen TH, Geagea JP, Radojevic JA, Sehhat K, Barua RS. Predictors of troponin elevation after percutaneous coronary intervention. Am J Cardiol 2004;93:747-750.
9. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145:522-528.
10. Natarajan MK, Kreatsoulas C, Velianou JL, Mehta SR, Pericak D, Goodhart DM. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 2004;93:750-753.
11. Okmen E, Kasikcioglu H, Sanli A, Uyarel H, Cam N. Correlations between cardiac troponin I, cardiac troponin T, and creatine phosphokinase MB elevation following successful percutaneous coronary intervention and prognostic value of each marker. J Invasive Cardiol 2005; 17:63-67.
12. The Beta-blocker Heart Attack Trial. Beta-blocker Heart Attack Study Group. JAMA 1981;246:2073-2074.
13. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985;6:199-226.
14. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
15. Harjai KJ, Stone GW, Boura J, Grines L, Garcia E, Brodie B, Cox D, O'Neill WW, Grines C. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003;91:655-660.
16. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone GW. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004; 43:1780-1787.
17. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation 2000;102:166-172.
18. Ellis SG, Brener SJ, Lincoff AM, Moliterno DJ, Whitlow PL, Schneider JP, Topol EJ. Beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. Circulation 2001;104:2685-2688.
19. Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A, Anzuini A, Uretsky BF. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003; 107:2914-2919.
20. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 2003;16:299-305.
21. Chan AW, Quinn MJ, Bhatt DL, Chew DP, Moliterno DJ, Topol EJ, Ellis SG. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:669-675.
22. Harris BM, Nageh T, Marsden JT, Thomas MR, Sherwood RA. Comparison of cardiac troponin T and I and CK-MB for the detection of minor myocardial damage during interventional cardiac procedures. Ann Clin Biochem 2000;37:764-769.
23. Billinger M, Raeber L, Seiler C, Windecker S, Meier B, Hess OM. Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol. Eur Heart J 2004;25:565-570.
24. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, Judd RM, Kim RJ. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
25. Kurz DJ, Naegeli B, Bertel O. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J 2000;139:35-43.
26. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, Erbel R. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-2183.
27. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678.
28. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352: 87-92.
29. Desmet WJ, Dens J, Coussement P, Van de Werf F. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart 2002;88:293-295.
30. Villari B, Ambrosio G, Golino P, Ragni M, Focaccio A, Tritto I, Salvatore M, Chiariello M. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993;125:11-23.
31. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-451.
32. Lipshultz SE, Somers MJ, Lipsitz SR, Colan SD, Jabs K, Rifai N. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 2003;112:79-86.